+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vaccine Market By Technology, Indication, and End Use: Global Opportunity Analysis and Industry Forecast, 2020-2027

  • ID: 5237509
  • Report
  • November 2020
  • Region: Global
  • 294 pages
  • Allied Analytics LLP
1 of 3
The global vaccine market accounted for $32,463 million in 2019 and is expected to reach $54,168 million by 2027, registering a CAGR of 6.6% from 2020 to 2027.

Vaccine is a biological preparation that is administered to produce acquired immunity in patients. Administration of vaccines aids to enhance the immune response against a specific pathogen. Vaccinations play a key role in sustaining people's health across different countries; hence, they are used in various national disease-prevention strategies. Due to the increased occurrence of both viral and bacterial infectious diseases, the demand for vaccines has grown over the past few years. Vaccinations are primarily provided to people of different ages, improving their immune system during their lives and ensuring defense against various forms of infectious diseases.

It is estimated that vaccine market is expected to experience significant market growth during the forecast period as there has been an increase in adoption in several countries across the globe by national immunization programs. In addition, surge in pneumococcal, meningococcal disease outbreaks in several countries has led to upsurge in demand for meningococcal vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products due to contamination are expected to impede the market growth. In contrast, high population base in emerging markets and global increase in healthcare spending provides significant growth opportunities for the meningococcal vaccine market.

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in 2019, and is expected to retain its dominance throughout the forecast period. This is attributed to factors such as well-equipped & better financed hospitals & clinics, high adoption rate for vaccine products, and sophisticated healthcare infrastructure. Moreover, the U.S. is the target area for top players in the market, owing to high awareness about vaccination. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential due to improvement in healthcare facilities, available disposable income, and rapidly developing economic conditions.

The global vaccine market is segmented on the basis of technology, indication, end user, and region. Depending on technology, the market is classified into recombinant & conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. By indication, the market is classified into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella; diphtheria, pertussis, & tetanus (DPT), polio, hepatitis, measles; mumps, & rubella (MMR), and other indications. According to end user, the market is segmented into pediatric, adults, and travelers. By region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, the UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key players operating in the vaccine market include Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZenecea, GlaxoSmithKline plc, Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, Novavax, Inc.

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing market opportunities.
  • A comprehensive analysis of the countries in Latin America is provided to determine the existing opportunities.
  • The key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS

By Technology type
  • Recombinant & Conjugate Vaccines
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Others
By Indication
  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella, Measles, Mumps, & Rubella
  • Diphtheria, Pertussis, & Tetanus {DPT}
  • Polio
  • Hepatitis
  • Other Indications
By End User
  • Pediatric
  • Adults
  • Travelers
By Region

North America
  • U.S.
  • Canada
  • Mexico
Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • AstraZenecea
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GSK
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis
  • Novavax, Inc.
  • Pfizer
  • Sanofi Aventis
  • Serum Institute of India Ltd
Note: Product cover images may vary from those shown
2 of 3
Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.2.1. List of Key Players Profiled in the Report
1.3. Research Methodology
1.3.1. Primary Research
1.3.2. Secondary Research
1.3.3. Analyst Tools and Models

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. CXO Perspective

Chapter 3: Market Overview
3.1. Market Definition and Scope
3.1.1. Top Winning Strategies, 2019
3.2. Top Player Positioning
3.2.1. Top Investment Pockets
3.3. Key Forces Shaping Vaccine Industry/Market
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Increase in Prevalence of Infectious Diseases
3.4.1.2. Surge in Immunization Programs Across the Globe
3.4.1.3. Increase in R&D Activities to Develop New Vaccine
3.4.2. Restraint
3.4.2.1. Longer Timelines Required for Vaccine Production
3.4.2.2. High Cost Associated With the Development of Vaccine
3.4.3. Opportunity
3.4.3.1. Growth Opportunities in the Emerging Markets
3.4.3.2. Increase in Healthcare Spending
3.4.4. Impact Analysis
3.1. Covid-19 Impact Analysis on Vaccine Market
3.1.1. Overview
3.1.2. Impact Analysis

Chapter 4: Vaccine Market, by Technology
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Recombinant & Conjugate Vaccine
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Analysis, by Country
4.3. Inactivated Vaccines
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Analysis, by Country
4.4. Live Attenuated Vaccines
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Analysis, by Country
4.5. Toxoid Vaccines
4.5.1. Key Market Trends, Growth Factors, and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Analysis, by Country
4.6. Other Vaccines
4.6.1. Key Market Trends, Growth Factors, and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Analysis, by Country

Chapter 5: Global Vaccine Market, by Indication
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Pneumococcal Disease
5.2.1. Key Market Trends, Growth Factors, and Opportunities
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Analysis, by Country
5.3. Influenza
5.3.1. Key Market Trends, Growth Factors, and Opportunities
5.3.2.`Market Size and Forecast, by Region
5.3.3. Market Analysis, by Country
5.4. Human Papilloma Virus
5.4.1. Key Market Trends, Growth Factors, and Opportunities
5.4.2. Market Size and Forecast, by Region
5.4.3. Market Analysis, by Country
5.5. Meningococcal Disease
5.5.1. Key Market Trends, Growth Factors, and Opportunities
5.5.2. Market Size and Forecast, by Region
5.5.3. Market Analysis, by Country
5.6. Rotavirus
5.6.1. Key Market Trends, Growth Factors, and Opportunities
5.6.2. Market Size and Forecast, by Region
5.6.3. Market Analysis, by Country
5.7. Varicella, Measles, Mumps, and Rubella (Mmr)
5.7.1. Key Market Trends, Growth Factors, and Opportunities
5.7.2. Market Size and Forecast, by Region
5.7.3. Market Analysis, by Country
5.8. Diptheria, Pertussis, and Tetanus (Dpt)
5.8.1. Key Market Trends, Growth Factors, and Opportunities
5.8.2. Market Size and Forecast, by Region
5.8.3. Market Analysis, by Country
5.9. Polio
5.9.1. Key Market Trends, Growth Factors, and Opportunities
5.9.2. Market Size and Forecast, by Region
5.9.3. Market Analysis, by Country
5.10. Hepatitis
5.10.1. Key Market Trends, Growth Factors, and Opportunities
5.10.2. Market Size and Forecast, by Region
5.10.3. Market Analysis, by Country
5.11. Other Indications
5.11.1. Key Market Trends, Growth Factors, and Opportunities
5.11.2. Market Size and Forecast, by Region
5.11.3. Market Analysis, by Country

Chapter 6: Vaccines Market, by End-user
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Pediatric Vaccines
6.2.1. Market Size and Forecast
6.2.2. Market Analysis, by Country
6.3. Adult Vaccines
6.3.1. Market Size and Forecast
6.3.2. Market Analysis, by Country
6.4. Travelers Vaccines
6.4.1. Market Size and Forecast
6.4.2. Market Analysis, by Country

Chapter 7: Global Vaccine Market, by Region
7.1. Overview
7.1.1. Market Size and Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, and Opportunities
7.2.2. Market Size and Forecast, by Country
7.2.3. Market Size and Forecast, by Technology
7.2.4. Market Size and Forecast, by Indication
7.2.5. Market Size and Forecast, by End-user
7.2.5.1. U.S. Market Size and Forecast, by Technology
7.2.5.2. Market Size and Forecast, by Indication
7.2.5.3. Market Size and Forecast, by End-user
7.2.5.4. Mexico Market Size and Forecast, by Technology
7.2.5.5. Mexico Market Size and Forecast, by Indication
7.2.5.6. Mexico Market Size and Forecast, by End-user
7.2.5.7. Canada Market Size and Forecast, by Technology
7.2.5.8. Canada Market Size and Forecast, by Indication
7.2.5.9. Canada Market Size and Forecast, by End-user
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, and Opportunities
7.3.2. Market Size and Forecast, by Country
7.3.3. Market Size and Forecast, by Technology
7.3.4. Market Size and Forecast, by Indication
7.3.5. Market Size and Forecast, by End-user
7.3.5.1. Germany Market Size and Forecast, by Technology
7.3.5.2. Germany Market Size and Forecast, by Indication
7.3.5.3. Germany Market Size and Forecast, by End-user
7.3.5.4. France Market Size and Forecast, by Technology
7.3.5.5. France Market Size and Forecast, by Indication
7.3.5.6. France Market Size and Forecast, by End-user
7.3.5.7. UK Market Size and Forecast, by Technology
7.3.5.8. UK Market Size and Forecast, by Indication
7.3.5.9. UK Market Size and Forecast, by End-user
7.3.5.10. Italy Market Size and Forecast, by Technology
7.3.5.11. Italy Market Size and Forecast, by Indication
7.3.5.12. Italy Market Size and Forecast, by End-user
7.3.5.13. Spain Market Size and Forecast, by Technology
7.3.5.14. Spain Market Size and Forecast, by Indication
7.3.5.15. Spain Market Size and Forecast, by End-user
7.3.5.16. Rest of Europe Market Size and Forecast, by Technology
7.3.5.17. Rest of Europe Market Size and Forecast, by Indication
7.3.5.18. Rest of Europe Market Size and Forecast, by End-user
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, and Opportunities
7.4.2. Market Size and Forecast, by Country
7.4.3. Market Size and Forecast, by Technology
7.4.4. Market Size and Forecast, by Indication
7.4.5. Market Size and Forecast, by End-user
7.4.5.1. Japan Market Size and Forecast, by Technology
7.4.5.2. Japan Market Size and Forecast, by Indication
7.4.5.3. Japan Market Size and Forecast, by End-user
7.4.5.4. China Market Size and Forecast, by Technology
7.4.5.5. China Market Size and Forecast, by Indication
7.4.5.6. China Market Size and Forecast, by End-user
7.4.5.7. India Market Size and Forecast, by Technology
7.4.5.8. India Market Size and Forecast, by Indication
7.4.5.9. India Market Size and Forecast, by End-user
7.4.5.10. Australia Market Size and Forecast, by Technology
7.4.5.11. Australia Market Size and Forecast, by Indication
7.4.5.12. Australia Market Size and Forecast, by End-user
7.4.5.13. Rest of Asia-Pacific Market Size and Forecast, by Technology
7.4.5.14. Rest of Asia-Pacific Market Size and Forecast, by Indication
7.4.5.15. Rest of Asia-Pacific Market Size and Forecast, by End-user
7.5. LAMEA
7.5.1. Key Market Trends, Growth Factors, and Opportunities
7.5.2. Market Size and Forecast, by Country
7.5.3. Market Size and Forecast, by Technology
7.5.4. Market Size and Forecast, by Indication
7.5.5. Market Size and Forecast, by End-user
7.5.5.1. Brazil Market Size and Forecast, by Technology
7.5.5.2. Brazil Market Size and Forecast, by Indication
7.5.5.3. Brazil Market Size and Forecast, by End-user
7.5.5.4. Saudi Arabia Market Size and Forecast, by Technology
7.5.5.5. Saudi Arabia Market Size and Forecast, by Indication
7.5.5.6. Saudi Arabia Market Size and Forecast, by End-user
7.5.5.7. South Africa Market Size and Forecast, by Technology
7.5.5.8. South Africa Market Size and Forecast, by Indication
7.5.5.9. South Africa Market Size and Forecast, by End-user
7.5.5.10. Rest of LAMEA Market Size and Forecast, by Technology
7.5.5.11. Rest of LAMEA Market Size and Forecast, by Indication
7.5.5.12. Rest of LAMEA Market Size and Forecast, by End-user

Chapter 8: Company Profiles
8.1. Astrazeneca plc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Product Portfolio
8.1.4. Business Performance
8.2. Csl Limited
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.3. Emergent Biosolutions Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.1. Key Strategic Moves and Developments
8.4. GlaxoSmithKline plc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.6. Key Strategic Moves and Developments
8.5. Johnson & Johnson
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves and Developments
8.6. Merck & Co. Inc.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves and Developments
8.7. Novavax, Inc.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. Pfizer Inc.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves and Developments
8.9. Sanofi S. A.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.9.6. Key Strategic Moves and Developments
8.10. Serum Institute of India Pvt. Ltd
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
Note: Product cover images may vary from those shown
3 of 3

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll